Epidemiology of nursing home dialysis patients—A hidden population

Eran Y. Bellin1 | Alice M. Hellebrand2 | Steven M. Kaplan2 | Jordan G. Ledvina2 | William T. Markis3 | Nathan W. Levin4 | Allen M. Kaufman2

1Departments of Epidemiology & Population Health and Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
2Dialyze Direct, Neptune City, New Jersey, USA
3WTM Consulting, Passaic, New Jersey, USA
4Internal Medicine, Mount Sinai Icahn School of Medicine, New York, New York, USA

Correspondence
Eran Y. Bellin, Departments of Epidemiology & Population Health and Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. Email: eranbellin@gmail.com

Abstract

Introduction: Dialysis patients are often discharged from hospitals to skilled nursing facilities (SNFs), but little has been published about their natural history.

Methods: Using electronic medical record data, we conducted a retrospective cohort study of nursing home patients treated with in-SNF hemodialysis from January 1, 2018 through June 20, 2020 within a dialysis organization across eight states. A dialytic episode began with the first in-SNF dialysis and was ended by hospitalization, death, transfer, or cessation of treatment. The clinical characteristics and natural history of these patients and their dialytic episodes are described.

Findings: Four thousand five hundred and ten patients experienced 9274 dialytic episodes. Dialytic episodes had a median duration of 18 days (IQR: 8–38) and were terminated by a hospitalization n = 5747 (62%), transfer n = 2638 (28%), death n = 568 (6%), dialysis withdrawal n = 129 (1.4%), recovered function n = 2 (0.02%), or other cause n = 6 (0.06%). Increased patient mortality was associated with advancing age, low serum creatinine, albumin, or sodium, and low pre-dialytic systolic blood pressure (sBP). U-shaped relationships to mortality were observed for intradialytic hypotension frequency and for post- > pre-hemodialysis sBP frequency. Prescription of dialysis five times weekly in the first 2 weeks was associated with better survival in the first 90 days (HR 0.77, CI 0.62–0.96; p < 0.02).

Discussion: Provision of in-SNF dialysis by an external dialysis organization enables discharge from the acute care setting for appropriate treatment with increased nursing contact time in an otherwise under-resourced environment. SNF ESRD patient clinical characteristics and outcomes are extensively characterized for the first time.

Keywords: epidemiology, ESRD, hemodialysis, intradialytic hypotension, mortality risk factors, nursing home
INTRODUCTION

Patients over 65 comprise 52% of annual US incident dialysis patients.1 In 2015–2017, reportedly 6.9% of incident ESRD patients resided in a skilled nursing facility (SNF)2—a likely underestimate.3 In the year preceding death, over one-third of medicare dialysis patients resided in a SNF.4 However, the medical literature is virtually blind to SNF dialysis residents.3,5–7 The latest comprehensive review summarizes reports in the decade preceding 2010.8 We report on our experience with this significant and growing population of hidden patients.

MATERIALS AND METHODS

Setting

Dialyze Direct provides onsite dialysis within SNFs, implementing a shorter and more frequent hemodialysis (MFD) treatment paradigm pursuant to a physician’s order, using NxStage System One technology and modeled to deliver 14 total hours of therapy per week. With a centralized administrative structure and distributed model of care (Figures S1–S3), senior clinical leadership develops protocols, procedures, and layered supervision across 134 nursing homes in eight states (Illinois, Ohio, Florida, Texas, New York, Pennsylvania, Indiana, Maryland). We report a retrospective study of all dialysis care data recorded by Dialyze Direct from January 1, 2018 through June 20, 2020 in either of two electronic medical records (EMR), GAIA (Gaia, Littleton, CO) and Clarity (Visonex, Green Bay, WI). This study adhered to the principles outlined in the Declaration of Helsinki. The Institutional Review Board (Western IRB, Olympia, WA) ruled the protocol exempt with full waiver of informed consent under 45 CFR § 46.104(d)2 of the Common Rule.

Analytical construct: Dialytic episode

The dialytic episode was defined as the interval starting from the first in-nursing home dialysis session, inclusive of all subsequent dialysis sessions, until terminated by hospitalization, transfer to another facility, death, withdrawal from therapy, or transfer to home. In readmission to the SNF, the first dialysis session upon readmission initiates a new dialytic episode. We report only completed dialytic episodes, excluding those beginning but not terminated within the timeframe of our study. For a given patient, an event life-history is created by combining these dialytic episodes, allowing for multiple hospitalizations in follow-up. Censorship is established by the last nondeath dialytic episode terminating event. In this framework, each dialytic episode can encompass many dialysis sessions and provide detailed insights into patient outcomes. Tabular data are provided by dialytic episode, representing every patient-admission to the SNF, or by patient, using only the first SNF admission.

Systolic blood pressures (sBP) pre- and post-hemodialysis (HD) recorded during standard care delivery were separately averaged across all dialyses within a dialytic episode to provide average values for each episode. Intradialytic hypotension (IDH) is defined according to Flythe with modification9–11 using a threshold absolute nadir sBP during a dialysis session. IDH is recognized by an absolute nadir sBP <90 mmHg, or alternatively, <100 mmHg in the case of a pre-HD sBP ≥150 mmHg. For each dialytic episode, we calculate the percent of dialyses in which at least one IDH event occurred and study its relationship to mortality. We also repeated this analysis for sBP <85 mmHg.

Peridialytic sBP changes were calculated as post-HD sBP minus pre-HD sBP and assessed for frequency per dialytic episode of positive peridialytic sBP (post-HD sBP > pre-HD sBP, by at least 5 mmHg).

Dialytic kinetic adequacy is defined as delivery of standard $Kt/V$ (std$Kt/V$) ≥2.0. Kinetics are measured at first HD and then repeatedly on the first Monday of each month with subsequent adjustments in the dialysis prescription as needed to achieve adequacy. Kinetic calculations are made using the formula developed by Leypoldt.12 Kinetic data are presented as the average std$Kt/V$ per dialytic episode.

The race/ethnicity variable was constructed sequentially by first assigning ethnicity and then delineating the non-Hispanic population as White, Black, or other/unknown.

All-cause mortality information is obtained from EMR and includes death in the nursing home as well as in the hospital when known.

Duration of dialysis is obtained from the vintage field in the EMR where there is considerable incompleteness and obvious errors, so we present this information as median and interquartile range. We attempt to calculate a lower limit estimate of incidence by including all unique patients in the denominator and all patients whose vintage calculates to zero at the time of first dialytic episode in the numerator.

Home discharge

Nurses administering in-nursing home dialysis perceived themselves as providing in-home dialysis, and within
their EMR vocabulary, even when patients were transferred back to their original domicile, they considered them conceptually “transferred to another dialysis unit.” Their entries for disposition in the EMR reflected this mindset and thus did not capture a distinction between true home discharge vs. transfer to another facility. Beginning in April 2020, we established a process of reeducation and asked the nurses to explicitly designate discharge to home domicile in the disposition table.

### Statistical method

Stata 16 (College Park, TX) was used for data management, descriptive statistics, and time to outcome analyses, including Kaplan–Meier survival statistics and graphs combining follow-up dialytic episodes with gaps to create a continuous event history to death or censorship for each patient. Multivariable survival analysis was performed with Cox Regression and proportionality assumption tested with Schoenfeld residuals. Associations are represented by hazard ratios (HR) and 95% confidence intervals (CI). Laboratory tests used for modeling comprise the first measure obtained in a dialytic episode.

Summary descriptions are provided as a modified Tukey five-point data summary (FPDS) with percentiles 5, 25, 50, 75, 95 provided. This exclusion of extremes prevents inferential error due to gross database outliers. In tables, missing data is implied by differing counts of relevant constituent observations. Aggregation of problem list diagnostic codes into Elixhauser and Charlson diagnostic categories was performed using the R library comorbidity.

### Intent and success in achieving 5×/week dialysis

Five times per week dialysis (MFD5) benefits patients with a gentler process requiring lower-volume ultrafiltration, which should yield shorter post-dialysis recovery times. Because Dialyze Direct’s patient population is elderly and frail, the majority of these patients suffer from certain co-morbidities that result in the local nephrologist of record prescribing MFD5. To evaluate achievement of this clinical goal, we define intent to treat by averaging dialysis prescriptions in the first two Sunday-through-Saturday intervals. We compare this calculated intent with the observed dialyses averaged over complete Sunday-through-Saturday intervals for the first 90 days of an episode. To evaluate association of MFD5 intent with survival, we apply the intent to treat paradigm for outcome attribution, assessing survival in the time period following established intent.

### RESULTS

#### Dialytic episode outcomes

From January 1, 2018 through June 20, 2020, a total of 4510 patients initiated and completed 9274 in-nursing home dialytic episodes under Dialyze Direct’s care. Demographics and primary dialysis access are provided (Table 1).

Dialytic episodes were terminated by a hospitalization \( n = 5747 \) (62%), transfer \( n = 2638 \) (28%), death \( n = 568 \) (6%), dialysis withdrawal \( n = 129 \) (1.4%), recovered function \( n = 2 \) (0.02%), or unspecified other cause \( n = 6 \) (0.06%). An additional 492 patients were known to have subsequently died during their hospitalization.

Four thousand four hundred and twenty hospitalizations were followed by a readmission to the same SNF. The median intervening duration of hospitalization was 6 days (IQR: 4–10).

One thousand eight hundred and sixty-six patients were readmitted to the SNF following a hospitalization. These readmitted patients had a median of three hospitalizations with SNF readmission (FPDS: 2, 2, 3, 4, 8).

The median duration of dialytic episode was 18 days (IQR: 8–38). Forty-three percent of episodes consisted of a length of stay \( \leq 2 \) weeks, with 10% staying 81 days or more.

Of the 4021 dialytic episodes discharged within 2 weeks, 2737 (68%) were hospitalized, 275 (7%) died, 945 (23.5%) were transferred out, 62 (2%) had dialysis withdrawn, and 2 (0.05%) were classified as “other.” An additional 236 of those hospitalized subsequently died.

Home discharge was evaluated following improved EMR protocol (see Methods) for the period May 1, 2020 until June 20, 2020. Of 546 qualifying dialytic episodes, 98 (18%) were discharged to home, 345 (63%) hospitalized, 74 (14%) died, 14 (2.6%) transferred to SNF, 9 (1.7%) had dialysis withdrawn, 1 (0.2%) recovered function, and 5 (0.9%) designated as “other.” Of 216 discharged patients with length of stay \( \leq 2 \) weeks, 149 (69%) were hospitalized, 27 (13%) died, 25 (12%) returned home, 7 (3%) had dialysis withdrawn, 6 (3%) transferred to SNF, and 2 (0.9%) were “other.”

### Clinical observations

#### Prevalence of documented clinical disease

Nursing documentation of clinical disease in the problem list section of the EMR suffers from incompleteness generally seen in most medical centers with 2315/9274 (25%) dialytic episodes failing to record even one clinical
problem. Notably, even when the problem list contained at least one entry, 1246/6959 (18%) did not designate a recognizable code for renal disease. With this proviso, we provide prevalent diseases documented in problem lists (Table 2). Weighted Charlson score (without age) for dialytic episodes was median 3 (IQR: 2–5) with 10% ≥ 6.

First laboratory values for patients’ first in-SNF dialysis under our care (Table S1) and for all recorded dialytic episodes (Table S2) are summarized in percentiles.

**Blood pressure and volume observations**

Median averaged pre-dialysis sBP was 128 mmHg (IQR: 115–144) with 10% having an averaged pre-dialysis sBP of at least 158 mmHg. (n = 9139). Median averaged post-dialysis sBP was 127 mmHg (IQR: 115–141) with 10% having an averaged post-dialysis sBP of at least 154 mmHg. (n = 9129).

Median volume decrease (net of all inputs and outputs) was 0.88 L per session (IQR: 0.53–1.3). Median time on dialysis was 170 min (IQR: 150–182). Median ultrafiltration rate for patients prescribed five times weekly dialysis was 4.9 ml/h/kg (IQR: 3.1–6.9) (UFR, spKt/V, stdKt/V by prescribed dialysis frequency, Table 3).

We have IDH data on 9139 of 9274 dialytic episodes. Fifty percent of these dialytic episodes manifested an IDH event in at least 14% of their dialysis sessions. Ten percent of dialytic episodes manifested an IDH event in at least 75% of their dialysis sessions.

We have IDH data from 4448 of 4510 patient first SNF admissions. Fifty percent of patients experienced an

### Table 1 Demographics for first nursing home admission, dialytic episodes

| Characteristics | First admission n = 4510 | Dialytic episodes n = 9274 |
|-----------------|--------------------------|---------------------------|
| Race/ethnicity  |                           |                           |
| White           | 1778 (39)                | 3652 (39)                 |
| Black           | 1521 (34)                | 3593 (39)                 |
| Hispanic        | 225 (5)                  | 487 (5)                   |
| Other/unknown   | 986 (22)                 | 1542 (17)                 |
| Age: mean (SD)  | 69 (12.4)                | 68 (12.4)                 |
| Age by Category, n (%) |                      |                           |
| 0–50            | 5 (7)                    | 737 (8)                   |
| 50–60           | 640 (14)                 | 1488 (16)                 |
| 60–70           | 1273 (28)                | 2684 (29)                 |
| 70–80           | 1433 (32)                | 2842 (31)                 |
| >80             | 849 (19)                 | 1523 (16)                 |
| Gender          |                           |                           |
| Male            | 2340 (52)                | 4702 (51)                 |
| Female          | 2170 (48)                | 4572 (49)                 |
| Primary vascular access |                    |                           |
| AV fistula—upper extremity | 1520 (34) | 2999 (32) |
| Fistula—lower extremity | 7 (0.2)     | 11 (0.1)    |
| AV graft—upper extremity | 433 (10)   | 964 (10)    |
| Graft—lower extremity | 15 (0.3)    | 26 (0.3)    |
| Catheter tunnel neck | 2454 (54) | 5034 (54) |
| Tunnel groin    | 14 (0.3)                 | 44 (0.5)                  |
| Neck (temporary)| 40 (0.9)                 | 82 (0.9)                  |
| Groin (temporary)| 22 (0.5)    | 93 (1)       |
| Unknown         | 5 (0.1)                  | 11 (0.1)                  |
| Vintage years (n) | n = 3564                | n = 7839                 |
| Median (IQR) years | 1.9 (0.1–5.1) | 2.1 (0.4–5.3) |

*Note: Data are presented as n (%) unless otherwise indicated. IQR, interquartile range.*
## TABLE 2  Problem list documented disease prevalence by first admission/dialytic episode (Elixhauser)

| Problem list documented disease                  | First admission \( n = 3181 \) | Dialytic episode \( n = 6959 \) | ICD 10 |
|------------------------------------------------|----------------------------------|---------------------------------|--------|
| Congestive heart failure                         | 940 (30)                        | 2184 (31)                      | I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5–I42.9, I43.x, I50.x, P29.0 |
| Cardiac arrhythmias                              | 533 (17)                        | 1179 (17)                      | I44.1 - I44.3, I45.6, I45.9, I47.x - I49.x, R00.0, R00.1, R00.8, T82.1, Z45.0, Z95.0 |
| Valvular disease                                 | 87 (3)                          | 188 (2.7)                      | A52.0, I05.x–I08.x, I09.1, I09.8, I34.x–I39.x, Q23.0–Q23.3, Z95.2–Z95.4 |
| Pulmonary circulation disorder                   | 73 (2)                          | 176 (2.5)                      | I26.x, I27.x, I28.0, I28.8, I28.9 |
| Peripheral vascular disorder                     | 290 (9)                         | 706 (10)                       | I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9 |
| Hypertension uncomplicated                        | 1111 (35)                       | 2572 (37)                      | I10.x |
| Hypertension complicated                         | 1174 (37)                       | 2931 (42)                      | I11.x–I13.x, I15.x |
| Paralysis                                        | 20 (0.6)                        | 74 (1.1)                       | G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0–G83.4, G83.9 |
| Other neurologic disorders                       | 181 (5.7)                       | 574 (8.2)                      | G10.x–G13.x, G20.x–G22.x, G25.4, G25.5, G31.2, G31.8, G31.9, G32.x, G35.x–G37.x, G40.x, G41.x, G93.1, G93.4, R47.0, R56.x |
| Chronic pulmonary disease                        | 427 (13.4)                      | 1142 (16.4)                    | I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4, J70.1, J70.3 |
| Diabetes uncomplicated                           | 512 (16)                        | 1351 (19.4)                    | E10.0, E10.1, E10.9, E11.0, E11.1, E11.9, E12.0, E12.1, E12.9, E13.0, E13.1, E13.9, E14.0, E14.1, E14.9 |
| Diabetes complicated                             | 1163 (37)                       | 2569 (37)                      | E10.2–E10.8, E11.2–E11.8, E12.2–E12.8, E13.2–E13.8, E14.2–E14.8 |
| Hypothyroidism                                   | 205 (6.4)                       | 470 (6.7)                      | E00.x–E03.x, E89.0 |
| Renal failure                                    | 2687 (84)                       | 5713 (82)                      | I12.0, I13.1, N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2 |
| Liver disease                                    | 116 (3.6)                       | 364 (5.2)                      | B18.x, I85.x, I86.4, I98.2, K70.x, K71.1, K71.3–K71.5, K71.7, K72.x–K74.x, K76.0, K76.2–K76.9, Z94.4 |
| Peptic ulcer disease                             | 7 (0.2)                         | 17 (0.2)                       | K25.7, K25.9, K26.7, K26.9, K27.7, K27.9, K28.7, K28.9 |
| Aids/HIV                                         | 22 (0.7)                        | 58 (0.8)                       | B20.x–B22.x, B24.x |
| Lymphoma                                         | 21 (0.7)                        | 49 (0.7)                       | C81.x–C85.x, C88.x, C96.x, C90.0, C90.2 |
| Metastatic cancer                                | 11 (0.3)                        | 20 (0.3)                       | C77.x–C80.x |
| Solid tumor without metastasis                   | 77 (2.4)                        | 206 (3)                        | C00.x–C26.x, C30.x–C34.x, C37.x–C41.x, C43.x, C45.x–C58.x, C60.x–C76.x, C97.x |
| Rheumatoid arthritis/collagen vascular disease   | 53 (1.7)                        | 165 (2.4)                      | L94.0, L94.1, L94.3, M05.x, M06.x, M08.x, M12.0, M12.3, M30.x, M31.0–M31.3, M32.x–M35.x, M45.x, M46.1, M46.8, M46.9 |
| Coagulopathy                                     | 116 (3.6)                       | 281 (4)                        | D65–D68.x, D69.1, D69.3–D69.6 |
| Obesity                                          | 176 (5.5)                       | 472 (6.8)                      | E66.x |
| Weight loss                                      | 111 (3.5)                       | 365 (5.2)                      | E40.x–E46.x, R63.4, R64 |
| Fluid and electrolyte disorders                  | 1854 (58)                       | 4165 (60)                      | E22.2, E86.x, E87.x |
| Blood loss anemia                                | 10 (0.3)                        | 44 (0.6)                       | D50.0 |
| Deficiency anemia                                | 1046 (33)                       | 2685 (39)                      | D50.8, D50.9, D51.x–D53.x |

(Continues)
IDH event in at least 14% of their dialysis sessions. Ten percent of patients experienced an IDH event in at least 75% of their dialysis sessions.

Evaluating nadir sBP <85 mmHg, 25% of patients had at least 20% of their sessions characterized as such, and 10% of patients were characterized by such a nadir in at least 50% of their dialysis sessions.

Intent and success in achieving 5×/week dialysis (MFD5)

Forty-three percent of dialytic episodes lack sufficient length of stay (≥14 days) to establish intent. Of the remaining 4669 dialytic episodes, 3339 (72%) were prescribed MFD5. Of those 3339 with demonstrated MFD5
## Table 4

Cox proportional hazards model for mortality adjusting for all other variables

| Percentile values within category | HR     | CI       | p-value | N\(^b\) (dialytic episodes) | 5th | 25th | 50th | 75th | 95th |
|----------------------------------|--------|----------|---------|-----------------------------|-----|------|------|------|------|
| **Age**                          |        |          |         |                             |     |      |      |      |      |
| 0–50 Base                        |        |          |         |                             |     |      |      |      |      |
| 50–60                            | 0.96   | (0.7, 1.3)| 0.8     | 1488                        | 51  | 54   | 56   | 58   | 60   |
| 60–70                            | 1.1    | (0.8, 1.5)| 0.5     | 2684                        | 61  | 63   | 66   | 68   | 69   |
| 70–80                            | 1.5    | (1.1, 2.0)| 0.006   | 2842                        | 71  | 72   | 74   | 77   | 79   |
| ≥80                              | 1.9    | (1.4, 2.6)| 0.000   | 1523                        | 80  | 82   | 84   | 88   | 91   |
| **% IDHa per dialytic Episode**  |        |          |         |                             |     |      |      |      |      |
| 0%–10%                          | 1.6    | (1.3, 2.0)| 0.000   | 4009                        | 0   | 0    | 0    | 2    | 8.3  |
| 10%–25%                         | Base   |          |         |                             | 10%| 13%  | 16%  | 20%  | 23%  |
| 25%–40%                         | 1.6    | (1.3, 2.1)| 0.000   | 1126                        | 25%| 27%  | 31%  | 33%  | 38%  |
| 40%–75%                         | 1.9    | (1.5, 2.3)| 0.000   | 1500                        | 40%| 47%  | 50%  | 62%  | 71%  |
| 75%–100%                        | 3.7    | (2.8, 4.7)| 0.000   | 958                         | 75%| 83%  | 100% | 100% | 100% | 100% | 100% |
| **Sodium (mg/dl)**               |        |          |         |                             |     |      |      |      |      |
| 0–130 Base                       | 1.5    | (1.2, 1.8)| 0.000   | 748                         | 122| 126  | 128  | 129  | 129  |
| 130–135                          | 1.1    | (0.9, 1.2)| 0.3     | 2879                        | 130| 131  | 133  | 134  | 134  |
| ≥135 Base                        |        |          |         |                             | 135| 136  | 138  | 141  | 142  |
| **Albumin (g/dl)**               |        |          |         |                             |     |      |      |      |      |
| 0–2.7 Base                       | 2.9    | (2.4, 3.6)| 0.000   | 1930                        | 1.8| 2.2  | 2.4  | 2.5  | 2.6  |
| 2.7–3.1                          | 1.9    | (1.6, 2.4)| 0.000   | 2826                        | 2.7| 2.8  | 2.9  | 3    | 3.1  |
| 3.1–3.5                          | 1.4    | (1.1, 1.8)| 0.001   | 2005                        | 3.2| 3.2  | 3.3  | 3.4  | 3.4  |
| ≥3.5 Base                        |        |          |         |                             | 3.5| 3.6  | 3.7  | 3.9  | 4.2  |
| **AvgBPsysPreHD (mmHg)**         |        |          |         |                             |     |      |      |      |      |
| 72–111.5 Base                    | 1.8    | (1.4, 2.3)| 0.000   | 1827                        | 90 | 99   | 104.5| 108  | 111  |
| 111.5–122.5                      | 1.4    | (1.2, 1.8)| 0.004   | 1828                        | 112| 114  | 117  | 120  | 122  |
| 122.5–133.5                      | 1.3    | (1.1, 1.7)| 0.012   | 1827                        | 123| 125  | 128  | 131  | 133  |
| 133.5–147.8                      | 0.86   | (0.67, 1.1)| 0.203  | 1828                        | 134| 137  | 140  | 144  | 147  |
| ≥147.8 Base                      |        |          |         |                             | 149| 152  | 158  | 167  | 184  |
| **BPsysPost > Pre (%)**          |        |          |         |                             |     |      |      |      |      |
| 0%–14.3% Base                    | 1.96   | (1.6, 2.4)| 0.000   | 1758                        | 0% | 0%   | 0%   | 8%   | 13%  |
| 14.3%–30% Base                   |        |          |         |                             | 14%| 18%  | 22%  | 25%  | 29%  |
| 30%–44% Base                     | 1      | (0.83,1.2)| 0.9    | 1809                        | 31%| 33%  | 36%  | 40%  | 43%  |
| 44%–60%                          | 0.96   | (0.79, 1.2)| 0.8    | 1697                        | 44%| 50%  | 50%  | 54%  | 58%  |
| >60%                             | 1.3    | (1.1, 1.6)| 0.01   | 1979                        | 60%| 67%  | 73%  | 93%  | 100% |
| **Creatinine (mg/dl)**           |        |          |         |                             |     |      |      |      |      |
| 0–3.7 Base                       | 1.3    | (1.03, 1.6)| 0.030  | 1839                        | 1.7| 2.5  | 3    | 3.3  | 3.6  |
| 3.7–4.9                          | 1.3    | (1.05, 1.7)| 0.016  | 1837                        | 3.7| 4    | 4.3  | 4.6  | 4.9  |
| 4.9–6.2                          | 1.2    | (0.93, 1.5)| 0.17   | 1831                        | 5   | 5.2  | 5.6  | 5.8  | 6.1  |
| 6.2–8                            | 0.99   | (0.79, 1.3)| 0.99   | 1841                        | 6.2| 6.5  | 7    | 7.4  | 7.8  |
| ≥8                                | Base   |          |         |                             | 8  | 8.6  | 9.4  | 10.7 | 13.4 |
| **Gender**                       |        |          |         |                             |     |      |      |      |      |
| Female Base                      |        |          |         |                             |     |      |      |      |      |
| Male                             | 1.01   | (0.89, 1.2)| 0.8    |                             |     |      |      |      |      |

(Continues)
intent, 1438 (43%) achieved consistent MFD5 treatment, 1149 (34%) achieved an average of 4.5–5 days per week dialysis, and 260 (7.8%) achieved 4.1–4.5 days per week dialysis. Of those with intent <5/C2 per week, only 66/1330 (5%) received an average dialysis frequency > 4/C2 per week in the first 90 days.

Survival

Following patients from first admission until death in nursing home or hospital demonstrated a strong effect of increasing age on cumulative mortality (Logrank; p < 0.0001).

Repeating the age-mortality analysis across two strata of IDH frequency (10%–25% vs. 75%–100%) visually demonstrates the impact of the IDH metric on survival (Figure 1).

A Cox proportional hazards model (Table 4) shows increased mortality with increasing age, decreasing serum sodium, albumin, creatinine concentrations, and lower pre-HD sBP. The lowest quintile of percentage dialyses with post-HD sBP > pre-HD sBP (0%–14.3%) has higher mortality compared with the highest quintile (>60%) (HR 1.5, CI [1.2–1.9]; p < 0.001) (different baseline than shown in Table 4).

Mortality results associated with percentage of dialysis sessions with IDH are counterintuitive, showing a U-shape around the base level of the second-lowest quintile IDH frequency. The lowest level has higher mortality than the base second-lowest level of IDH (HR 1.6, CI [1.3–2.0]; p < 0.000). Higher IDH percent levels show the expected increase in mortality (HR 1.6, 1.9, 3.7; p = 0.000, for levels 3, 4, and 5, respectively).

Increasing IDH quintiles are inversely related to pre-HD average sBP with a −0.47 linear regression coefficient (CI [−0.49, −0.45]; p = 0.000) for IDH quintiles regressed on quintiles of pre-HD average sBP (Table 5). A sensitivity analysis using Cox proportional hazards model stratifying by quintiles of pre-HD average sBP continues to demonstrate the U-shaped relationship of IDH frequency to mortality for each of the lower two quintiles of pre-HD average sBP (Tables S3 and S4).

### Table 4 (Continued)

| Race/ethnicity       | HR   | CI          | p-value | N (dialytic episodes) | 5th  | 25th | 50th  | 75th | 95th |
|----------------------|------|-------------|---------|-----------------------|------|------|-------|------|------|
| White                | Base |             |         |                       |      |      |       |      |      |
| Black                | 1.1  | (0.96, 1.3) | 0.15    |                       |      |      |       |      |      |
| Hispanic             | 0.97 | (0.72, 1.3) | 0.88    |                       |      |      |       |      |      |
| Other/unknown        | 1.5  | (1.3, 1.8)  | 0.000   |                       |      |      |       |      |      |

Note: Bold denotes statistically significant, p-value <0.05.

Abbreviations: BPsys, systolic blood pressure; CI, 95% confidence interval; HR, hazard ratio; IDH, intradialytic hypotension; Pre-HD, pre-hemodialysis.

*Percent of dialyses during a nursing home stay with at least one episode of intradialytic hypotension.

### Table 5

Percentiles of averaged pre-hemodialysis systolic blood pressure stratified by quintiles of % intradialytic hypotension

| Quintile % IDH<sup>a</sup> per dialytic episode | N  | Percentile of averaged pre-HD systolic BP | 5th | 25th | Median | 75th | 95th |
|------------------------------------------------|----|----------------------------------------|-----|------|--------|------|------|
| 0%–10%                                         | 4009 | 110 | 124 | 137 | 151 | 173 |
| 10%–25%                                        | 1546 | 108 | 120 | 130 | 143 | 163 |
| 25%–40%                                        | 1126 | 103 | 114 | 124 | 139 | 163 |
| 40%–75%                                        | 1500 | 98  | 107 | 116 | 129 | 153 |
| 75%–100%                                       | 958  | 85  | 97  | 105 | 118 | 150 |
| Total                                          | 9139 | 99  | 115 | 128 | 144 | 167 |

Note: Blood pressures expressed in mmHg.

Abbreviations: BP, blood pressure; HD, hemodialysis.

*Percent of dialyses during a nursing home stay with at least one episode of intradialytic hypotension.
Neither gender nor defined race/ethnicity had a significant impact on survival.

Proportional hazard was not violated \((p = 0.45)\).

Intent to treat MFD5 was associated with significantly increased survival in the first 90 days of a dialytic episode (Logrank \(p = 0.035\)). A cox proportional hazards model utilizing the variables described above indicated MFD5 was protective (HR 0.83, CI [0.74–0.92]; \(p = 0.001\)) (proportionality not rejected; \(p = 0.83\)). The actual weekly treatment received by those with MFD5 intent during the first 90 days of SNF residence was a mean of 4.6 treatments compared with 3.3 for those without MFD5 intent (mean difference 1.27, CI [1.23–1.31]; \(p = 0.000\)).

The last tenth of the study observation period overlaps with the onset of the COVID-19 pandemic’s outbreak in the United States. COVID-19 testing in nursing homes was limited and death certificates were unavailable to us, but we can infer a significant impact of the epidemic from mortality analyses (Figure S4).

Nursing home context and service contact time is detailed (Figure S5).

**DISCUSSION**

We describe a heretofore hidden nursing home dialysis population and their natural history in terms of length of stay, hospitalization, return to home, and death.

The average ultrafiltration rate (UFR) in thrice weekly outpatient dialysis was previously reported as 10 ml/h/kg across thousands of patients within a large dialysis organization.\(^2\) Patients in our population with MFD5 prescription had a remarkable median UFR of 4.9 ml/h/kg (IQR: 3.1–6.9), highlighting exceptional management of volume removal with this mode of treatment. This treatment paradigm potentially averts high UFR-associated mortality.\(^23\)

In our patient population, reduced UFR cannot be explained simply by increased dialysis frequency. Reduced access to discretionary salt and water in the nursing home population could partially explain a lower UFR. In addition, it is possible that these vulnerable and frail patients, among the most susceptible to the punishing effects of intradialytic volume shifts, experience a reset of avidity for salt and water when released from repeated systemic trauma associated with higher UFR and more aggressive volume shifts of 3 days weekly dialysis.\(^24–26\)

Our admission std\(Kt/V\) goal is \(\geq 2\), and we achieved std\(Kt/V\) median 2.2 (IQR: 2–2.4). At the fifth percentile of dialytic episodes, we note a low std\(Kt/V\) of 1.64. Review of the data revealed that these low values are found in patients with short length of stay, with early hospital returns precluding the protocol-driven adjustments we utilize for optimization with longer dwelling patients.

In our population, low blood pressure is associated with increased mortality—a fact recognized in other HD populations.\(^27–36\) A number of explanations have been proposed to explain this traditional risk factor paradox.\(^36,37\) We believe this statistical association in our patient population is a marker of pathology, in contrast to the causal relationship in the reverse direction as traditionally understood for much of the general population. The lowest quintile pre-HD sBP in our population is extraordinarily low (FPDS: 90, 99, 104.5, 108, 110.7). We suspect that this low sBP is indicative of a significant deterioration from a prior healthier stage in the lives of these patients when their baseline sBP was higher. Thus, their low pre-dialysis sBP is a marker of frailty reflective of poor cardiac output and/or advanced autonomic dysfunction with impaired sympathetic response\(^38\) and increased risk of death.

In some studies sBP tested in outpatient dialysis centers has not shown a relationship to mortality, in contrast to ambulatory home blood pressure evaluations.\(^39,40\) It is possible that a nursing home pre-dialysis sBP measurement is more akin to an at-home measurement without confounders observed in the dialysis center setting.

In the general dialysis population, a rise in peridialytic sBP is believed indicative of inadequate dialysis fluid management with residual volume overload.\(^9,11,22\) This produces an unacceptable time-averaged blood pressure that is expected to ultimately result in poor outcomes. In our patient population, those experiencing the highest frequency (\(>60\%\)) of increased post-HD sBP have a greater hazard of death compared to second-lowest quintile baseline (14.3%–30%) (HR 1.3, CI [1.1–1.6]; \(p = 0.012\)). However, paradoxically, those patients with the lowest frequency of elevated post-HD sBP (0%–14.3%) also have a greater risk of death compared to baseline (HR 1.96, CI [1.6–2.4]; \(p = 0.000\)) (Table 4). A comparison using the highest quintile as baseline reveals that the lowest quintile has lower survival (HR 1.5, CI [1.2–1.9]; \(p = 0.000\)). The inability to occasionally manifest increased post-HD sBP likely reflects cardiac and/or autonomic frailty.

Similarly, we observe a U-shaped impact of intradialytic hypotension with the best survival at the second-lowest level of percent IDH (10%–25%). Higher and lower frequencies of IDH have statistically significantly worse outcomes (Table 4). The relationship of high frequency of IDH and high mortality seems straightforward. Poor cardiac function and poor autonomic reserve is indicative of a state of frailty and carries the expectation of frequent hypotension when stressed by the volume removal of dialysis, resulting in high mortality due
to this state of frailty. By this logic, we would therefore expect the lowest level of percent IDH, reflective of the least frail, to have the least mortality, yet we note that the lowest level (0%–10%) has statistically worse mortality than the second-lowest level (10%–25%) (HR 1.6, CI [1.3–2.0]; \( p = 0.000 \)).

A potential explanation beyond absolute IDH frequency accounts for a “dialysis practitioner chagrin response” to observed hypotension and its functional selection of the frailest for the lowest quintile. It is possible that in response to observing IDH events in a patient, a practitioner dramatically reduces their efforts at volume removal, attempting to eliminate all IDH. Successfully eliminating IDH would leave an already compromised patient with increased post-dialysis volume, thereby unwittingly increasing mortality risk.

In this scenario, exposing the patient to some degree of IDH risk, within a certain frequency threshold, may maximize dialysis benefit. We intend to explore this hypothesis with future detailed analyses.

Low pre-dialytic serum creatinine reflects lower muscle mass, and it as well as low serum albumin indicate malnutrition or inanition. These were as expected\(^{41,42}\) associated with high mortality. Hyponatremia as reported elsewhere\(^{43}\) was also associated with mortality. The mechanism of hyponatremia in the elderly dialysis patient population is related but not limited to dilutional retention of hypotonic fluid and/or nonosmotic skin and muscle compartmentalization of sodium, the latter possibly related to potassium depletion,\(^{44}\) or other cell membrane abnormalities.\(^{45–47}\)

In the 1990s in an effort to encourage the care of dialysis patients in SNFs, the National Kidney Foundation created regional workshops to foster interactions between nursing homes and dialysis staff.\(^{48}\) Rapid turnover of nursing home staff defeated the project. A sustainable program must have procedural consistency, economies of scale across many institutions, and clear benefits to all stakeholders. The Dialyze Direct approach amortizes costs and supervision across nursing homes and geographic regions, providing a stable, expert workforce to manage these complex patients with dedicated care.

It is anticipated that onsite SNF dialysis will continue to grow because of value alignment among the four stakeholders—hospital, nursing home, patient, and payor (federal government). Onsite SNF dialysis enables the hospital to discharge patients earlier, reducing their length of stay and reserving space for those requiring acute care intervention. The nursing home is enabled to accept more complex patients and benefit financially from better reimbursement without needing to invest in a complex staffing infrastructure. Onsite dialysis also frees the SNF from the cost and resource burden of transportation to local dialysis centers and the disruption of rehabilitation programs. For the patient, the SNF provides an appropriate alternative setting when acute care is no longer needed. The hospital routine of frequent vital signs monitoring and off-hour disruptions that no longer add value can now be replaced by the more relaxed pace of the SNF. Onsite dialysis also frees the patient from disruptive transportation and interruption of physical therapy and rehabilitation. We observed a lower risk of death in the first 90 days of dialytic episode for those with MFD5 intent, which points to possible outcome benefit from in-SNF MFD5. Of course, without a randomized controlled trial, we cannot establish causality or rule out potential physician biases which may underlie physician MFD5 choice. For the payor, proper transition to lower acute care site promotes more efficient targeted interventions appropriate for the needs of the patient. In this setting, meaningful interventions can be applied and evaluated for cost reduction and improved quality of care.

Our study is limited by lack of complete death or vintage information, as we were unable to secure access to CMS-2746 death notification or CMS-2728 dialysis initiation forms. CMS policy restricts access to identified patient-level data for research exclusively to nonprofit entities. Cause of hospitalization is not captured in a retrievable manner in our EMR systems, which will be the focus of a future quality initiative. Finally, information on home discharge was gathered over the period May 1, 2020–June 20, 2020, coincident with the COVID-19 pandemic in the US, so our analysis may not be an accurate reflection of home transfers in nonpandemic times. Likewise, the ability of nurses to carry out the intended MFD5 treatment was impacted to some degree during the pandemic due to illness-induced staff shortages.

Detailed referral data were not available to us. Our best estimate was that roughly 90% of dialytic episodes occurred in individuals receiving dialysis in a post-acute care setting: 85% of which are comprised of prevalent ESRD and 15% (683/4510) incident ESRD. Ten percent of dialytic episodes occurred in long-term SNF residents with prevalent ESRD.

We provide the first detailed clinical and administrative summary of a hidden, growing, and needy population of dialysis patients. Future efforts will focus on detailed clinical analysis of interventions and outcomes with enhanced data collection driven by our quality improvement initiatives.

ACKNOWLEDGMENTS
We thank Dr Eric Weinhandl, Senior Epidemiologist of Hennepin Healthcare Research Institute in Minneapolis,
Minnesota for helpful comments and reference guidance. We also thank Rina Rogov for assistance with obtaining literature references.

CONFLICT OF INTEREST
Allen M. Kaufman, Alice M. Hellebrand, and Jordan G. Ledvina are current employees of Dialyze Direct and hold stock and/or stock options in Dialyze Direct. Steven M. Kaplan is a current employee of Dialyze Direct. Nathan W. Levin is a consultant for Dialyze Direct and chair of its Medical Advisory Board. Eran Y. Bellin is a consultant epidemiologist for Dialyze Direct, and William T. Markis is a consultant research analyst and medical writer for Dialyze Direct.

ORCID
William T. Markis https://orcid.org/0000-0002-1157-3627

REFERENCES
1. USRDS Renal data extraction and referencing (RenDER) system. Available from: https://render.usrds.org/render/xrender.phtml.
2. United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Reference Table C.4(2). Available from: https://www.usrds.org/annual-data-report/.
3. Bowling CB, Zhang R, Franch H, Huang Y, Mirk A, McClellan WM, et al. Underreporting of nursing home utilization on the CMS-2728 in older incident dialysis patients and implications for assessing mortality risk. BMC Nephrol. 2015;16:32.
4. Kurella Tamura M, Montez-Rath ME, Hall YN, Katz R, O’Hare AM. Advance directives and end-of-life care among nursing home residents receiving maintenance dialysis. Clin J Am Soc Nephrol. 2017;12:435–42.
5. Bowling CB, Plantinga L, Hall RK, Mirk A, Zhang R, Kutner N. Association of nondisease-specific problems with mortality, long-term care, and functional impairment among older adults who require skilled nursing care after dialysis initiation. Clin J Am Soc Nephrol. 2016;11:2218–24.
6. Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, et al. Association of race and age with survival among patients undergoing dialysis. JAMA. 2011;306:620–6.
7. Kurella Tamura M, Covinsky KE, Chertov GM, Yaffe K, Landefeld CS, McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med. 2009;361:1539–47.
8. Hall RK, O’Hare AM, Anderson RA, Colón-Emeric CS. End-stage renal disease in nursing homes: A systematic review. J Am Med Dir Assoc. 2013;14:242–7.
9. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015;26:724–34.
10. Assimon MM, Flythe JE. Definitions of intradialytic hypotension. Semin Dial. 2017;30:464–72.
11. Assimon MM, Wang L, Flythe JE. Intradialytic hypertension frequency and short-term clinical outcomes among individuals receiving maintenance hemodialysis. Am J Hypertens. 2018;31:329–39.
12. Leypoldt JK, Jaber BL, Zimmerman DL. Predicting treatment dose for novel therapies using urea standard Kt/V. Semin Dial. 2004;17:142–5.
13. Cleves MA, Gould W, Marchenko YV. An introduction to survival analysis using Stata. College Station, Texas: Revised third edition. edn. Stata Press; 2016.
14. Tukey JW. Exploratory data analysis. Reading, MA: Addison-Wesley Pub. Co.; 1977.
15. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–82.
16. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9.
17. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47:626–33.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–83.
19. Gasparini A. Comorbidity: An R package for computing comorbidity scores. J Open Source Software. 2018;3:648.
20. Gasparini ASH, Williman J. The R Package comorbidity. Available from: https://cran.r-project.org/web/packages/comorbidity/index.html.
21. Meystre SM, Haug PJ. Randomized controlled trial of an automated problem list with improved sensitivity. Int J Med Inform. 2008;77:602–12.
22. Flythe JE, Assimon MM, Wenger JB, Wang L. Ultrafiltration rates and the quality incentive program: Proposed measure definitions and their potential dialysis facility implications. Clin J Am Soc Nephrol. 2016;11:1422–33.
23. Assimon MM, Wenger JB, Wang L, Flythe JE. Ultrafiltration rate and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2016;68:911–22.
24. Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in the Netherlands: Effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant. 1998;13:2853–60.
25. Mistiaen P. Thirst, interdialytic weight gain, and thirst-interventions in hemodialysis patients: A literature review. Nephrol Nurs J. 2001;28:601–4, 610-603. quiz 614–605.
26. Saad E, Charras B, Raj DS. Hypertension control with daily dialysis. Semin Dial. 2004;17:295–8.
27. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996;49:1379–85.
28. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LYC, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33:507–17.

29. Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;48:606–15.

30. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561–9.

31. Bansal N, McCulloch CE, Lin F, et al. Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: The CRIC study (Chronic Renal Insufficiency Cohort). Hypertension. 2017;70:435–43.

32. Bansal N, McCulloch CE, Rahman M, Kusek JW, Anderson AH, Xie D, et al. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: The chronic renal insufficiency cohort study. Hypertension. 2015;65:93–100.

33. Chou JA, Streja E, Nguyen DV, Rhee CM, Obi Y, Inrig JK, et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant. 2018;33:149–59.

34. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–20.

35. Dasgupta I, Thomas GN, Clarke J, Sitch A, Martin J, Bieber B, et al. Associations between hemodialysis facility practices to manage fluid volume and intradialytic hypotension and patient outcomes. Clin J Am Soc Nephrol. 2019;14:385–93.

36. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808.

37. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY. Reverse epidemiology: A spurious hypothesis or a hardcore reality? Blood Purif. 2005;23:57–63.

38. Daugirdas JT. Dialysis hypotension: A hemodynamic analysis. Kidney Int. 1991;39:233–46.

39. Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension. 2010;55:762–8.

40. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2:1228–34.

41. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int. 1998;54:627–36.

42. Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int. 2002;62:2238–45.

43. Rhee CM, Ayus JC, Kalantar-Zadeh K. Hyponatremia in the dialysis population. Kidney Int Rep. 2019;4:769–80.

44. Laragh JH. The effect of potassium chloride on hyponatremia. J Clin Invest. 1954;33:807–18.

45. Titze J, Lang R, Illies C, Schwind KH, Kirsch KA, Dietsch P, et al. Osmotically inactive skin Na+ storage in rats. Am J Physiol Renal Physiol. 2008;295:F1752–63.

46. Titze J, Dahlmann A, Lerchl K, Kopp C, Rakova N, Schröder A, et al. Spooky sodium balance. Kidney Int. 2014;85:759–67.

47. Ziomber A, Machnik A, Dahlmann A, Dietsch P, Beck FX, Wagner H, et al. Sodium-, potassium-, chloride-, and bicarbonate-related effects on blood pressure and electrolyte homeostasis in deoxycorticosterone acetate-treated rats. Am J Physiol Renal Physiol. 2008;295:F1752–63.

48. Tong EM, Nissenson AR. Dialysis in nursing homes. Semin Dial. 2002;15:103–6.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Bellin EY, Hellebrand AM, Kaplan SM, et al. Epidemiology of nursing home dialysis patients—A hidden population. Hemodialysis International. 2021;1:12. https://doi.org/10.1111/hdi.12943